-
Je něco špatně v tomto záznamu ?
Interferon gamma release assay has potential in the prediction of chronic graft-versus-host disease in recipients of myeloablative allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis
M. Šťastná-Marková, P. Pecherková, Š. Němečková, J. Kryštofová, Š. Vaníková, J. Vydra, K. Roubalová
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, pozorovací studie
- MeSH
- chronická nemoc MeSH
- cyklofosfamid * terapeutické užití MeSH
- dospělí MeSH
- hematologické nádory terapie MeSH
- homologní transplantace MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- myeloablativní agonisté terapeutické užití MeSH
- nemoc štěpu proti hostiteli * diagnóza prevence a kontrola etiologie MeSH
- příprava pacienta k transplantaci * metody MeSH
- prospektivní studie MeSH
- senioři MeSH
- test pomocí interferonu gama MeSH
- transplantace hematopoetických kmenových buněk * škodlivé účinky MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
BACKGROUND: The rate of immune reconstitution after allogeneic hematopoietic stem cell transplantation (allo-HSCT) plays the principal role in the development of serious post-transplant complications. However, the post-transplantation course has a significant impact on shaping the immune system of the recipient, per se, thus representing risk factors for subsequent unfavorable outcomes. The predictive power of an interferon gamma (IFNγ) release assay (IGRA) on graft-versus-host disease (GVHD) or hematological relapse in recipients of allo-HSCT treated with post-transplantation cyclophosphamide and the impact of these complications on the restoration of cellular immune responsiveness was evaluated. STUDY DESIGN: A prospective observational study in which 62 adult patients with myeloid hematological malignancies who underwent allo-HSCT with a myeloablative conditioning regimen combined with post-transplantation cyclophosphamide were enrolled. Clinical data were collected and the IGRA was performed before commencement of the conditioning regimen and for 12 months post-allo-HSCT. Multivariate Cox regression and logistic regression models with backward stepwise analyses were used to calculate the predictive values for acute or chronic GVHD, or hematological relapse. RESULTS: Pre-transplantation and early post-transplantation IGRA values and other selected covariables (age, diagnosis, relapse risk, conditioning type, pre-T lymphocyte count, and donor sex), enabled prediction of the 12-month incidence of chronic GVHD with positive and negative predictive values of 75 % and 88 %, respectively. However, the IGRA did not improve the predictive value for acute GVHD or hematological relapse. Patients with myelodysplastic syndrome (MDS) had a significantly lower pre-transplant IGRA value (p = 0.021) and a delayed IFNγ response in IGRA, post-HSCT, than patients with acute myeloid leukemia (AML) (p = 0.015 and p = 0.0063 for 3 and 4 months post-HSCT, respectively). CONCLUSIONS: The IGRA can be used to monitor the recovery of total cellular immunity, post-HSCT and it has shown potential for use in personalized post-transplantation care. In the multivariate backward stepwise logistic regression model, pre-and early post-transplantation IGRA values showed potential for predicting chronic GVHD. Patients with MDS had a significantly lower pre-transplantation IGRA value and delayed IFNγ response in IGRA, post-HSCT, than patients with AML.
Department of Biostatistics Institute of Hematology and Blood Transfusion Prague Czech Republic
Department of Immunology Institute of Hematology and Blood Transfusion Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010058
- 003
- CZ-PrNML
- 005
- 20250429134903.0
- 007
- ta
- 008
- 250415e20241221ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.trim.2024.102166 $2 doi
- 035 __
- $a (PubMed)39716645
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Šťastná-Marková, Markéta $u Transplantation and Intensive Care Unit, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 245 10
- $a Interferon gamma release assay has potential in the prediction of chronic graft-versus-host disease in recipients of myeloablative allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis / $c M. Šťastná-Marková, P. Pecherková, Š. Němečková, J. Kryštofová, Š. Vaníková, J. Vydra, K. Roubalová
- 520 9_
- $a BACKGROUND: The rate of immune reconstitution after allogeneic hematopoietic stem cell transplantation (allo-HSCT) plays the principal role in the development of serious post-transplant complications. However, the post-transplantation course has a significant impact on shaping the immune system of the recipient, per se, thus representing risk factors for subsequent unfavorable outcomes. The predictive power of an interferon gamma (IFNγ) release assay (IGRA) on graft-versus-host disease (GVHD) or hematological relapse in recipients of allo-HSCT treated with post-transplantation cyclophosphamide and the impact of these complications on the restoration of cellular immune responsiveness was evaluated. STUDY DESIGN: A prospective observational study in which 62 adult patients with myeloid hematological malignancies who underwent allo-HSCT with a myeloablative conditioning regimen combined with post-transplantation cyclophosphamide were enrolled. Clinical data were collected and the IGRA was performed before commencement of the conditioning regimen and for 12 months post-allo-HSCT. Multivariate Cox regression and logistic regression models with backward stepwise analyses were used to calculate the predictive values for acute or chronic GVHD, or hematological relapse. RESULTS: Pre-transplantation and early post-transplantation IGRA values and other selected covariables (age, diagnosis, relapse risk, conditioning type, pre-T lymphocyte count, and donor sex), enabled prediction of the 12-month incidence of chronic GVHD with positive and negative predictive values of 75 % and 88 %, respectively. However, the IGRA did not improve the predictive value for acute GVHD or hematological relapse. Patients with myelodysplastic syndrome (MDS) had a significantly lower pre-transplant IGRA value (p = 0.021) and a delayed IFNγ response in IGRA, post-HSCT, than patients with acute myeloid leukemia (AML) (p = 0.015 and p = 0.0063 for 3 and 4 months post-HSCT, respectively). CONCLUSIONS: The IGRA can be used to monitor the recovery of total cellular immunity, post-HSCT and it has shown potential for use in personalized post-transplantation care. In the multivariate backward stepwise logistic regression model, pre-and early post-transplantation IGRA values showed potential for predicting chronic GVHD. Patients with MDS had a significantly lower pre-transplantation IGRA value and delayed IFNγ response in IGRA, post-HSCT, than patients with AML.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nemoc štěpu proti hostiteli $x diagnóza $x prevence a kontrola $x etiologie $7 D006086
- 650 12
- $a cyklofosfamid $x terapeutické užití $7 D003520
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a příprava pacienta k transplantaci $x metody $7 D019172
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a chronická nemoc $7 D002908
- 650 _2
- $a test pomocí interferonu gama $7 D059425
- 650 _2
- $a homologní transplantace $7 D014184
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a hematologické nádory $x terapie $7 D019337
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a myeloablativní agonisté $x terapeutické užití $7 D019653
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Pecherková, Pavla $u Department of Biostatistics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Němečková, Šárka $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Kryštofová, Jitka $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Vaníková, Šárka $u Department of Immunomonitoring and Flow Cytometry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Vydra, Jan $u Transplantation and Intensive Care Unit, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Roubalová, Kateřina $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Electronic address: kroubalova@centrum.cz
- 773 0_
- $w MED00006022 $t Transplant immunology $x 1878-5492 $g Roč. 88 (20241221), s. 102166
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39716645 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134859 $b ABA008
- 999 __
- $a ok $b bmc $g 2311431 $s 1247139
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 88 $c - $d 102166 $e 20241221 $i 1878-5492 $m Transplant immunology $n Transpl Immunol $x MED00006022
- LZP __
- $a Pubmed-20250415